Anticardiolipin Antibodies in Clinical Conditions Associated with a Risk of Thrombotic Events

Hughes, J.; Davies, J. A.

doi:10.1016/s0049-3848(97)00299-5

Cited by 17 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…APA exerts a procoagulant effect resulting in thrombosis mainly of the larger veins and arteries. Indeed, one of the key features in antiphospholipid syndrome is vascular thrombosis occurring in 23–58% of patients with APA 29 …”

Section: Discussionmentioning

confidence: 99%

The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease

Shaker¹,

El-Deen²,

Hadidi³

et al. 2006

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease

Shaker¹,

El-Deen²,

Hadidi³

et al. 2006

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…suggested that the titers of anticardiolipin antibodies did not differ among the patient groups including acute myocardial infarction, acute myocardial ischemia and stable coronary artery disease consisting of coronary artery bypass surgery and balloon angioplasty patients, and that neither of the aCL antibodies was associated with recurrent coronary events in a Finnish study [16]. Hughes and colleagues reported that aCL antibodies are higher in patients with angina and acute myocardial infarction than normal controls in a United Kingdom population [17]. Ranzolin et al .…”

Section: Discussionmentioning

confidence: 99%

The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study

Ertaş¹,

Can

Acet³

et al. 2013

pwki

View full text Add to dashboard Cite

IntroductionAcute myocardial infarction (AMI) will probably remain the most important cause of death over the next decades. Traditional risk factors of atherosclerosis could not exactly explain the development of acute coronary events such as AMI. Antiphospholipid antibody syndrome is a disorder characterized by the development of arterial and venous thrombosis.AimIn this study, we investigated the relations between acute myocardial infarction and anti-phospholipid antibody syndrome in our population representing Aegean Region people characteristics.Material and methodsOne hundred patients with acute myocardial infarction were consecutively included in the study (group I) and one hundred age and sex matched people with similar risk factors were enrolled in the study as a control group (group II). Anticardiolipin antibody (aCL) IgM and IgG levels were measured in the two groups. Levels of aCL IgG ≥ 48 U/ml and/or aCL IgM ≥ 44 U/ml were accepted as positive and significant.ResultsIn patients with acute myocardial infarction, 5 patients (5%) had positive IgM levels and 8 patients (8%) were found to have positive IgG levels. All cases in the control group had negative aCL IgM and IgG antibody levels. These results were accepted as significant for both aCL antibodies between patients and controls (p < 0.001).ConclusionsWe concluded that aCL antibody levels are also higher in a small proportion of patients with acute myocardial infarction than controls in our region, also, and these results suggest that there may be an immune stimulus in the pathogenesis of acute coronary events.

show abstract

“…The antiphospholipid antibodies, which include the LAC and ACL, are a group of antibodies directed predominantly against anionic phospholipids 2,4,5 . When these antibodies are seen with thrombotic or neurological disorders, thrombocytopenia or fetal loss, the syndrome of APS is present 2 . Increased levels of APAs are common in infections 7 and malignancies but in these situations clinical APS is not seen 3 .…”

Section: Discussionmentioning

confidence: 99%

“…The term "antiphospholipid antibody syndrome" (APS) describes patients who have persistent elevation of antiphospholipid antibodies (APAs) of which anticardiolipin has been the most frequently investigated 1 . APS is deemed to be present when a patient has raised APAs and one of the following clinical conditions: venous or arterial thrombosis, neurologic disease, thrombocytopenia or recurrent fetal wastage 2 .…”

mentioning

confidence: 99%

Acute Autoimmune Cardiomyopathy in Primary Antiphospholipid Antibody Syndrome

Nagappan

Lodge

2002

Anaesth Intensive Care

View full text Add to dashboard Cite

We present a case of acute pulmonary oedema as the first presentation of autoimmune cardiomyopathy in primary antiphospholipid antibody syndrome in a patient who had no previous cardiac history. Five days of methylprednisolone at 500 mg/day followed by 100 mg/day for 10 days and then a weaning course of oral prednisone resulted in effective resolution of the acute diffuse cardiomyopathy. Her cardiac status became clinically and echocardiographically normal. We illustrate the effectiveness of immunosuppressive therapy as an adjunct to standard anti-failure measures in such presentations and we outline the association between antiphospholipid antibodies and cardiac dysfunction.

show abstract

Anticardiolipin Antibodies in Clinical Conditions Associated with a Risk of Thrombotic Events

Cited by 17 publications

References 26 publications

The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease

The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease

The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study

Acute Autoimmune Cardiomyopathy in Primary Antiphospholipid Antibody Syndrome

Contact Info

Product

Resources

About